Most cited papers from Dermira (United States)

Dermira (United States)

What are the most cited papers from Dermira (United States)?

The most cited paper from Dermira (United States) is "The immunogenetics of Psoriasis: A comprehensive review" (Jamie Lynn Harden, James G. Krueger, Anne M. Bowcock, 2015), with 620 citations. Next come "Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis" (345) and "Physiology and Pathophysiology of Itch" (285).

Published TypeFieldAccessCitations

Showing 50 of 53 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The immunogenetics of Psoriasis: A comprehensive review Jamie Lynn Harden, James G. Krueger, Anne M. Bowcock · Journal of Autoimmunity Open access	26 Jul 2015	620
2	Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield et al. · JAMA Dermatology Open access	26 Feb 2020	345
3	Physiology and Pathophysiology of Itch Ferda Cevikbas, Ethan A. Lerner · Physiological Reviews ReviewOpen access	23 Dec 2019	285
4	Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches Matthew Moyle, Ferda Cevikbas, Jamie Lynn Harden et al. · Experimental Dermatology Open access	2 Mar 2019	163
5	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) Alice Bendix Gottlieb, Andrew Blauvelt, Diamant Thaçi et al. · Journal of the American Academy of Dermatology Open access	13 Apr 2018	157
6	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT) Mark Lebwohl, Andrew Blauvelt, Carle F. Paul et al. · Journal of the American Academy of Dermatology Open access	13 Apr 2018	133
7	Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials Dee Anna Glaser, Adelaide Ann Hebert, Alexander Nast et al. · Journal of the American Academy of Dermatology Open access	9 Jul 2018	81
8	Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials David M. Pariser, Adelaide Ann Hebert, Janice Drew et al. · American Journal of Clinical Dermatology Open access	30 Oct 2018	42
9	Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials Andrew Blauvelt, Kristian Reich, Mark Lebwohl et al. · Journal of the European Academy of Dermatology and Venereology Open access	22 Sep 2018	38
10	Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials Adelaide Ann Hebert, Dee Anna Glaser, Lawrence Green et al. · Pediatric Dermatology Open access	19 Nov 2018	35
11	Inhibition of Sebum Production with the Acetyl Coenzyme A Carboxylase Inhibitor Olumacostat Glasaretil David W. C. Hunt, Geoffrey C. Winters, Roger William Brownsey et al. · Journal of Investigative Dermatology Open access	Mar 2017	35
12	Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study Robert Bissonnette, Yves P. Poulin, Janice Drew et al. · Journal of the American Academy of Dermatology	28 Oct 2016	35
13	A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis Dee Anna Glaser, Adelaide Ann Hebert, Alexander Nast et al. · American Journal of Clinical Dermatology Open access	20 May 2019	34
14	A systematic evidence-based review of treatments for primary hyperhidrosis Michael E. Stuart, Sheri A. Strite, Kristin Khalaf Gillard · Journal of Drug Assessment Open access	28 Nov 2020	26
15	Paired Transcriptomic and Proteomic Analysis Implicates IL-1β in the Pathogenesis of Papulopustular Rosacea Explants Jamie Lynn Harden, Yi‐Hsien Shih, Jin Xu et al. · Journal of Investigative Dermatology Open access	14 Sep 2020	23
16	Treatment Patterns, Depression, and Anxiety Among US Patients Diagnosed with Hyperhidrosis: A Retrospective Cohort Study Stephanie Z. Klein, MICHAEL L. HULL, Kristin Khalaf Gillard et al. · Dermatology and Therapy Open access	11 Sep 2020	23
17	Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label extension study Adelaide Ann Hebert, Dee Anna Glaser, Lawrence Green et al. · Pediatric Dermatology Open access	8 Mar 2020	23
18	Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis David M. Pariser, Edward L. Lain, Richard D. Mamelok et al. · Clinical Pharmacokinetics Open access	12 Jan 2021	17
19	Development and validation of the Axillary Sweating Daily Diary: a patient-reported outcome measure to assess axillary sweating severity Lauren M. Nelson, Dana Britt DiBenedetti, David M. Pariser et al. · Journal of Patient-Reported Outcomes Open access	5 Sep 2019	17
20	The Changing Roles of Industry and Academia Eugene A. Bauer, David E. Cohen · Journal of Investigative Dermatology Open access	13 Feb 2012	15
21	The challenge of change: Resilience traits in Women’s Dermatological Society Forum participants by generation Catherine M. Ludwig, Amaris N. Geisler, Jennifer M. Fernandez et al. · International Journal of Women’s Dermatology Open access	25 Jun 2020	8
22	DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity David W. C. Hunt, Iordanka A. Ivanova, Lina Dagnino · Tissue Barriers Open access	Jun 2020	7
23	Cost-effectiveness of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis Lisa M. Bloudek, Kristin Khalaf Gillard, Victor B. Nguyen et al. · Journal of Medical Economics Open access	Dec 2020	6
24	Pathophysiology of Rosacea Ethan A. Lerner, Ferda Cevikbas · Updates in clinical dermatology Book chapter	2020	4
25	Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Phototherapy Donovan G. Kearns, Shelley K. Uppal, Vipawee S. Chat et al. · Cutis Open access	Aug 2020	4
26	Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield et al. · SKIN The Journal of Cutaneous Medicine Open access	9 Nov 2019	4
27	528 DRM01, a novel, topical sebum inhibitor for the treatment of acne J. Masure, Didier H. Bonnel, Jennifer L. Stauber et al. · Journal of Investigative Dermatology Open access	28 Apr 2016	4
28	INDIVIDUAL ARTICLE: Fixed Combination Calcipotriene/Betamethasone (Cal/BDP) Cream: Evaluating the Role of Polyaphron Dispersion (PAD) Technology in Psoriasis Treatment Rasika Reddy, Samiya Khan, Leon Kircik et al. · Journal of Drugs in Dermatology Open access	Jul 2023	1
29	26301 Pharmacokinetic analyses show limited systemic exposure with topical glycopyrronium tosylate David M. Pariser, Edward L. Lain, Richard D. Mamelok et al. · Journal of the American Academy of Dermatology	7 Aug 2021	1
30	51. Clinical Presentation and Quality of Life Burden Associated With Hyperhidrosis in Children and Adolescents Zakiya P. Rice, Lisa J. Pieretti, Allison P. Wheeler et al. · Journal of Adolescent Health	Feb 2021	1
31	872 IL-1β is a potential central mediator to Papulopustular Rosacea pathology as determined by paired transcriptomic and proteomic analysis Jamie Lynn Harden, Yi‐Hsien Shih, Divya Rajendran et al. · Journal of Investigative Dermatology Open access	16 Jun 2020	1
32	Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Overview of 3 Randomized Controlled Trials Andrew Blauvelt, Kristian Reich, Mark Lebwohl et al. · SKIN The Journal of Cutaneous Medicine Open access	23 Feb 2018	1
33	Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Primary Axillary Hyperhydrosis Dee Anna Glaser, Adelaide Ann Hebert, Alexander Nast et al. · SKIN The Journal of Cutaneous Medicine Open access	23 Feb 2018	1
34	From the Bench to the Bedside and Back: An Essential Journey Eugene A. Bauer · Journal of Investigative Dermatology Open access	10 Feb 2015	1
35	Efficacy and Safety of Fixed-Dose Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne Vulgaris in Children and Adolescents Lawrence F. Eichenfield, Adelaide Ann Hebert, Julie C Harper et al. · SKIN The Journal of Cutaneous Medicine Open access	18 Mar 2024	0
36	Analysis of patient attitudes and behavior regarding dermatologic care during the COVID-19 pandemic: a survey-based study at a single academic institution Duohuai Gao, J S Kahn, S R Cohen et al. · Dermatology Online Journal Open access	29 Dec 2022	0
37	Laser Lithotripsy Physics Joel M.H. Teichman, Jinze Qiu, Kang Dong Wook et al. · Urolithiasis Book chapter	2012	0
38	Post-hoc Analyses of Lebrikizumab Phase 3 Trials (LAVOLTA I and II): Enhanced Efficacy in Patients With Prior Exacerbations and Elevated Baseline FENO or Blood Eosinophilia Ellen Sher, Phillip E. Korenblat, Guy Brusselle et al. · Journal of Allergy and Clinical Immunology	Feb 2022	0
39	27567 Clinical management of ocular events with topical glycopyrronium tosylate in the treatment of primary axillary hyperhidrosis Dee Anna Glaser, Ramanan Gopalan, N.C. Visitacion · Journal of the American Academy of Dermatology	7 Aug 2021	0
40	Lockyer Valley numerical groundwater flow simulation model Catherine Moore, Leif Wolf, Sreekanth Janardhanan et al. Open access	2013	0
41	16428 Lebrikizumab, a high-affinity interleukin-13 inhibitor, improves clinical manifestations in moderate to severe atopic dermatitis: Time course of response from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield et al. · Journal of the American Academy of Dermatology	27 Nov 2020	0
42	Quality of Life Impact and Awareness of Primary Focal Hyperhidrosis in Children and Adolescents ZP Rice, LJ Pieretti, Anne Wheeler et al. · SKIN The Journal of Cutaneous Medicine Open access	27 Oct 2020	0
43	Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements Emma Guttman‐Yassky, Andrew Blauvelt, Lawrence F. Eichenfield et al. · SKIN The Journal of Cutaneous Medicine Open access	27 Oct 2020	0
44	Depression, Anxiety, Health Care Costs, and Utilization among Patients with Hyperhidrosis in a Real‑World Database Analysis MICHAEL L. HULL, KK Gillard, Jesse Peterson-Brandt et al. · SKIN The Journal of Cutaneous Medicine Open access	27 Oct 2020	0
45	Management of Psoriasis With Biologics in Clinical Practice: An Update for 2020 Mirjana G. Ivanic, Sheida Naderi-Azad, Shikha Walia et al. · Cutis Open access	Aug 2020	0
46	911 Lebrikizumab attenuates the neuronal enhancement of pruritus through IL-13 consistent with clinical anti-itch effects observed in phase 2b moderate-to-severe atopic dermatitis patients Eric Lawrence Simpson, Amy S. Paller, Ferda Cevikbas · Journal of Investigative Dermatology Open access	16 Jun 2020	0
47	Limited Systemic Exposure with Topical Glycopyrronium Tosylate across Multiple Studies in Healthy Volunteers and Patients with Primary Axillary Hyperhidrosis David M. Pariser, Edward L. Lain, Richard D. Mamelok et al. · SKIN The Journal of Cutaneous Medicine Open access	9 Nov 2019	0
48	Epidemiology Of Hyperhidrosis in the United States: A Systematic Literature Review KK Gillard, LM Bloudek · Value in Health ReviewOpen access	May 2018	0
49	Traitement du psoriasis par certolizumab pégol : résultats de l’étude de phase 3 CIMPACT, multicentrique, randomisée, contrôlée vs. étanercept et vs. placebo Mark Lebwohl, Carle F. Paul, Howard L. Sofen et al. · Annales de Dermatologie et de Vénéréologie	25 Nov 2017	0
50	Traitement du psoriasis par certolizumab pegol : résultats des études de phase 3 CIMPASI 1&2, multicentriques, randomisées et contrôlées vs. PBO D. Vandame, Alice Bendix Gottlieb, Andrew Blauvelt et al. · Annales de Dermatologie et de Vénéréologie	25 Nov 2017	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.